Dennis N. Berman

CIK: 0001273858

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)16 (72.7%)

Compensation grants

Other (G, F, J, C, D, …)6 (27.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IKT

Inhibikase Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (22 total)

IKT
Inhibikase Therapeutics, Inc.
Jun 30, 2025
Award(A)
Stock Option (Right to Buy)
Direct
108.2K shares-
IKT
Inhibikase Therapeutics, Inc.
Feb 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
39.6K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
30K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
21.9K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
3.8K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
6.7K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
6.7K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
3.8K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
6.7K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
6.7K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
6.7K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
6.7K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
30K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
30K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
1.1K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Direct
1.1K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
3.8K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Disposition(D)
Stock Option (Right to Buy)
Indirect
21.9K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 21, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
21.9K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
344.5K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
172.2K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
316.6K shares-

		Type	Shares	Price		Ownership
Jun 30, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	108,176	-	-	Direct
Feb 14, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	39,620	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	30,000	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	21,854	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	3,780	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	6,667	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	6,667	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	3,780	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	6,667	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	6,667	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	6,667	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	6,667	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	30,000	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	30,000	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	1,138	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	1,138	-	-	Direct
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	3,780	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	21,854	-	-	Indirect
Jan 21, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	21,854	-	-	Indirect
Jan 3, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	344,452	-	-	Direct
Jan 3, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	172,191	-	-	Direct
Jan 3, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	316,647	-	-	Direct

1-22 of 22 transactions

About BERMAN DENNIS N

BERMAN DENNIS N (SEC CIK 0001273858) files insider reports with the SEC as Director of Inhibikase Therapeutics, Inc. (IKT).

Signal8 holds 5 ownership filings by BERMAN DENNIS N, all Form 4s, filed between Jan 7, 2025 and Jul 2, 2025. Those filings report 22 transactions, from Jan 3, 2025 to Jun 30, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on BERMAN DENNIS N's filings is in ATLANTA, GA.

Recent filings by BERMAN DENNIS N

Jun 30, 2025: Grant or award of IKT derivative securities (Form 4, code A).
Feb 14, 2025: Grant or award of IKT derivative securities (Form 4, code A).
Jan 21, 2025: Grants or awards of IKT derivative securities (6 lines, Form 4, code A).
Jan 21, 2025: Disposition to issuer transaction of IKT derivative securities (Form 4, code D).
Jan 21, 2025: Grant or award of IKT derivative securities (Form 4, code A).

Other insiders filing for Inhibikase Therapeutics, Inc. (IKT)

Wasserman Scott M., Director
RA CAPITAL MANAGEMENT, L.P., 10% Owner
Aurentz Vincent, Director
Cabell Christopher, President & Head of R&D
Munshi Amit, Director
Iwicki Mark T, Chief Executive Officer

How to read Form 4 transaction codes